经评估，公司认为四川华信资质等方面合规有效，履职保持独立性，勤勉尽 责，公允表达意见，具体情况如下： 一、资质条件 四川华信（集团）会计师事务所（特殊普通合伙）初始成立于 1988 年 6 月， 2013 年 11 月 27 日改制为特殊普通合伙企业。 注册地址：泸州市江阳中路 28 号楼三单元 2 号，总部办公地址：成都市武 侯区洗面桥街 18 号金茂礼都南 28 楼；首席合伙人：李武林。 四川和邦生物科技股份有限公司 对会计师事务所 2024 年度履职情况的评估报告 四川和邦生物科技股份有限公司（以下简称"公司"或"本公司"）聘请四 川华信（集团）会计师事务所（特殊普通合伙）（以下简称"四川华信"）作为公 司 2024 年度年报审计机构。根据财政部、国资委及证监会颁布的《国有企业、 上市公司选聘会计师事务所管理办法》，公司对四川华信 2024 年审计过程中的履 职情况进行评估。 项目质量控制复核人唐辉近三年无因执业行为受到刑事处罚，近三年因执业 行为受到监督管理措施 2 次。2022 年 12 月，四川华信收到浙江监管局【2022】 144 号行政监管措施决定书涉及质量控制复核人唐辉，四川华信已按要求整改 ...

根据《上海证券交易所上市公司自律监管指引第 3 号行业信息披露：第十三 号——化工》及相关要求，四川和邦生物科技股份有限公司（以下简称"公司"） 现将 2024 年度主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 产量（吨） | 销量（吨） | 营业收入（万元） | | --- | --- | --- | --- | | 联碱化工类产品 | 2,425,531.95 | 1,530,991.18 | 172,537.90 | | 农药及中间体、副产品 | 251,539.92 | 231,266.62 | 303,117.77 | | 营养剂及中间体、副产品 | 164,192.92 | 168,438.03 | 120,001.59 | 注 1：联碱化工类产品包括：碳酸钠、氯化铵； 注 2：农药及中间体、副产品包括：双甘膦、草甘膦原粉、磷酸氢二钠等； | | | 四川和邦生物科技股份有限公司 2024 年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年度公司主 ...

四川和邦生物科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 公司代码：603077 公司简称：和邦生物 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 2024年度内部控制评价报告 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实 ...

证券代码：603077 证券简称：和邦生物 公告编号：2025-021 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司关于使用 自有资金、外汇、信用证、银行承兑汇票等方式 支付募投项目款项并以募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 四川和邦生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日 召开第六届董事会第二十四次会议、第六届监事会第十次会议，审议通过了《关 于使用自有资金、外汇、信用证、银行承兑汇票等方式支付募投项目款项并以募 集资金等额置换的议案》，同意公司及子公司在募投项目实施期间根据实际情况 使用自有资金、外汇、信用证、银行承兑汇票等方式支付募投项目所需部分资金， 并以募集资金等额置换。现将具体情况公告如下： 根据公司《向不特定对象发行可转换公司债券募集说明书》中披露的募集资 金使用计划，公司募集资金投资项目如下： 单位：万元 | 序号 | 项目名称 | | 项目总投资额 | 本次募集资金拟投入金额 | | --- | --- | -- ...

关于四川和邦生物科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：四川和邦生物科技股份有限公司 审计单位：四川华信（集团）会计师事务所（特殊普通合伙） 联系电话：028-85560449 | 四川华信(集团)会计师事务所 地址:成都市洗面桥街18号金茂礼都南28楼 | | --- | | 电话:(028) 85560449 | | (特殊普通合伙) 传真:(028)85560449 | | 邮编: 610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) 电邮: schxzhb@hxcpa.com.cn | 关于四川和邦生物科技股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况的专项说明 川华信专(2025) 第 0598 号 目录: 1、关于四川和邦生物科技股份有限公司 2024年度非经营性资金占用及其他关 联资金往来情况的专项说明 关于四川和邦生物科技股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来情况的专项说明 川华信专(2025) 第 0598 号 四川和邦 ...

证券代码：603077 证券简称：和邦生物 公告编号：2025-017 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●拟聘任的会计师事务所名称：四川华信（集团）会计师事务所（特殊普通 合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 四川华信（集团）会计师事务所（特殊普通合伙）（以下简称"四川华信"）， 初始成立于 1988 年 6 月，2013 年 11 月 27 日改制为特殊普通合伙企业。 注册地址：泸州市江阳中路 28 号楼三单元 2 号；总部办公地址：成都市武 侯区洗面桥街 18 号金茂礼都南 28 楼；首席合伙人：李武林。 四川华信自 1997 年开始一直从事证券服务业务。 1.基本信息 本项目合伙人：张兰 张兰，注册会计师注册时间为 1995 年 5 月，自 1995 年 3 月起加入四川华信 并从事证券业务类业务，2021 年开始为本公司提供审计服务。近三年签署的上 市公 ...

一、 召开会议的基本情况 | 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-023 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东大会召开日期：2025年5月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一) 股东大会类型和届次 2024年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 26 日 14 点 30 分 召开地点：四川省乐山市五通桥区和邦大数据中心行政大楼 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 26 日 至202 ...

证券代码：603077 证券简称：和邦生物 公告编号：2025-013 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 第六届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 四川和邦生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日 在公司会议室，以现场会议的方式召开了第六届监事会第十次会议。会议通知已 于 2025 年 4 月 18 日分别以专人送达、电子邮件或传真等方式发出。本次会议由 公司监事会主席陈静女士召集和主持。本次会议应到监事 3 名，实到 3 名。本次 会议的召集、召开符合《中华人民共和国公司法》和《四川和邦生物科技股份有 限公司章程》的规定。会议审议并通过了如下议案： 一、审议通过《公司监事会 2024 年度工作报告》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交公司股东大会审议。 二、审议通过《关于公司 2024 年度利润分配的预案》 利益的情形，符合公司经营现状，有利于公司的持续、稳定、健康发展。 表决结果 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,725,715,319.77, a decrease of 13.68% compared to ¥1,999,261,196.40 in the same period last year[3] - Net profit attributable to shareholders was ¥12,517,312.95, down 57.99% from ¥29,792,564.09 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥8,483,951.04, a decline of 69.79% compared to ¥28,084,784.36 in the previous year[3] - The basic earnings per share decreased by 55.56% to ¥0.0016 from ¥0.0036 in the same period last year[4] - The diluted earnings per share fell by 66.67% to ¥0.0012 from ¥0.0036 year-on-year[4] - The weighted average return on net assets was 0.0674%, down from 0.1545%, a decrease of 0.0871 percentage points[4] - Total operating revenue for Q1 2025 was ¥1,725,715,319.77, a decrease of 13.7% compared to ¥1,999,261,196.40 in Q1 2024[16] - Net profit for Q1 2025 was ¥7,535,116.90, a decline of 72.2% from ¥27,143,210.75 in Q1 2024[17] - Total comprehensive income for Q1 2025 was ¥22,040,365.17, down from ¥28,631,801.49 in Q1 2024[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥29,844,949,250.05, an increase of 0.66% from ¥29,649,734,539.88 at the end of the previous year[4] - The company's current assets totaled CNY 13.88 billion, down from CNY 14.00 billion at the end of 2024, with cash and cash equivalents at CNY 7.12 billion[12] - Accounts receivable increased to CNY 880.41 million from CNY 809.76 million, reflecting a growth of approximately 8.7%[12] - The company's inventory rose to CNY 4.67 billion, compared to CNY 4.54 billion, indicating an increase of about 2.5%[12] - Total liabilities increased to CNY 11.12 billion from CNY 10.64 billion, representing a growth of approximately 4.4%[14] - The company's long-term borrowings rose significantly to CNY 1.66 billion from CNY 766.44 million, indicating a substantial increase[14] - The equity attributable to shareholders decreased slightly to CNY 18.47 billion from CNY 18.63 billion, a decline of about 0.8%[14] Cash Flow and Investments - Cash flow from operating activities for Q1 2025 was negative at -¥54,591,408.70, an improvement from -¥433,373,338.57 in Q1 2024[20] - Cash inflow from investment activities in Q1 2025 totaled ¥30,851,147.38, compared to ¥4,911,030.97 in Q1 2024[20] - The net cash flow from investing activities was -$338.08 million, compared to -$239.70 million in the previous period, indicating an increase in cash outflow for investments[21] - Cash inflow from financing activities totaled $2.28 billion, up from $1.53 billion, reflecting a significant increase in borrowing[21] - The net cash flow from financing activities was $605.02 million, compared to $419.36 million in the previous period, showing improved cash generation from financing[21] - The cash and cash equivalents at the end of the period amounted to $7.07 billion, an increase from $2.65 billion at the end of the previous period[21] - The company reported a total cash outflow from investing activities of $368.93 million, compared to $244.61 million previously, indicating increased investment activity[21] - The cash outflow for debt repayment was $1.32 billion, significantly higher than $517.69 million in the previous period, reflecting a focus on reducing debt[21] - The net increase in cash and cash equivalents for the period was $214.13 million, a recovery from a decrease of -$253.78 million in the previous period[21] Projects and Future Plans - The company is advancing several major projects, including the completion of the Guang'an project and the initiation of AI control in experimental setups[9] - The company aims to achieve high-phosphorus and high-silicon phosphate rock sales from the Wonarah project in Australia within the year[9] - The company has outlined plans for the Nigeria mining rights cooperation project, targeting scientific and intelligent mining practices to commence in May 2025[9] Expenses and Impairments - Research and development expenses for Q1 2025 were ¥4,536,209.31, a decrease of 45.4% from ¥8,346,347.48 in Q1 2024[16] - The company reported a significant increase in tax expenses, with Q1 2025 tax expenses at ¥13,108,894.20 compared to ¥16,465,391.27 in Q1 2024[17] - The company experienced a credit impairment loss of -¥7,366,037.14 in Q1 2025, an improvement from -¥14,527,656.52 in Q1 2024[16]

Financial Performance - In 2024, the company's operating revenue was approximately CNY 8.55 billion, a decrease of 3.13% compared to CNY 8.82 billion in 2023[25]. - The net profit attributable to shareholders was CNY 31.46 million, down 97.55% from CNY 1.28 billion in 2023[25]. - The basic earnings per share dropped to CNY 0.0038, a decline of 97.42% from CNY 0.1474 in the previous year[24]. - The net cash flow from operating activities increased significantly to CNY 467.93 million, up 482.50% from CNY 80.33 million in 2023[25]. - The total assets at the end of 2024 were CNY 29.65 billion, an increase of 20.81% from CNY 24.54 billion at the end of 2023[25]. - The company's net assets attributable to shareholders decreased by 4.85% to CNY 18.63 billion from CNY 19.58 billion in 2023[25]. - The company experienced a significant decline in profit margins due to market price reductions for some products, influenced by macroeconomic conditions[26]. - The diluted earnings per share for 2024 was CNY 0.0037, reflecting a decrease of 97.49% from CNY 0.1474 in 2023[26]. - The company reported a quarterly net profit of CNY -189.85 million in Q4 2024, contrasting with profits in the earlier quarters[28]. - Non-recurring gains and losses for 2024 totaled CNY 7.97 million, significantly lower than CNY 47.78 million in 2023[31]. Dividend Policy - The company plans to distribute a total of RMB 161 million in cash dividends for the first half of 2024, with no cash dividends or capital reserve transfers planned for the full year[5]. - The company has no plans for cash dividends or capital reserve transfers for the fiscal year 2024, focusing instead on reinvestment for growth[5]. - The company has a clear cash dividend policy that aligns with its articles of association and protects minority shareholders' rights[183]. - The cumulative cash dividend amount over the last three accounting years is approximately 553 million RMB, with an average cash dividend ratio of 32.40% of the average net profit[188]. - The net profit attributable to ordinary shareholders for the most recent accounting year is approximately 31.46 million RMB[188]. - The company has not proposed any cash profit distribution plan for 2024, citing compliance with its profit distribution policy and future development needs[182]. Project Development and Investment - The company is currently developing several projects, including a 500,000-ton glyphosate project in Guang'an and a 200,000-ton glyphosate project in Indonesia, which are critical for future revenue growth[8]. - The company plans to accelerate the construction of three phosphate mining projects, aiming for a total production capacity of over 4 million tons per year within 1-2 years[38]. - The company has signed an agreement with AFRICORP HOLDINGS LIMITED to jointly develop 22 lithium mines and 6 tin mines in Nigeria, with detailed exploration set to start in May 2025[38]. - The company has successfully completed the issuance of convertible bonds totaling RMB 460 million, with funds earmarked for the investment and construction of a 500,000 tons per year glyphosate project[45]. - The company is advancing the Wonarah phosphate project in Australia, aiming for high-phosphorus and high-silica phosphate rock sales within the year[43]. - The company has increased its R&D investment in both the chemical and mining sectors, emphasizing process technology innovation[36]. - The company aims to leverage the current low prices of raw materials and services to significantly reduce project investment costs[42]. Market Conditions and Pricing - The company reported that its product gross margin is significantly affected by market price fluctuations, indicating potential volatility in financial performance[8]. - The company emphasizes the importance of market conditions and policy changes on raw material prices, which could affect production costs and profitability[8]. - The price of glyphosate fluctuated between RMB 24,000 and RMB 25,000 per ton during the reporting period, experiencing a "high then low" trend[51]. - The domestic phosphate rock market is expected to maintain a tight supply-demand balance, with long-term price stability anticipated due to resource scarcity[47]. - The overall decline in revenue was primarily attributed to falling product prices across various sectors[94]. Operational Efficiency and Workforce - The company has hired 184 new employees in the mining sector, with 30% holding university degrees, laying a foundation for future development[39]. - The company has introduced 18 expert-level talents in the mining sector, enhancing its technical capabilities in exploration and processing[82]. - The company has a diverse workforce with 3,571 production personnel, 190 sales personnel, 801 technical personnel, 72 financial personnel, and 752 administrative personnel[177]. - The company offers a salary policy that includes a base salary plus performance-based pay, encouraging employee development through special allowances and internal competition mechanisms[178]. Environmental and Compliance - The company has been recognized as a key pollutant discharge unit by local environmental authorities, emphasizing its commitment to environmental protection and sustainable development[197]. - The company has implemented a comprehensive wastewater treatment system, ensuring compliance with environmental regulations through centralized treatment and monitoring[197]. - The company has established a robust internal control system, with no significant deficiencies reported during the period[192]. - The company’s internal control effectiveness was audited by an external firm, resulting in a standard unqualified opinion[193]. - All emissions are within the limits set by the respective discharge permits and standards[199][200]. Governance and Management - The company continues to adhere to the insider information management system as per regulations, ensuring compliance with governance standards[160]. - The company has not engaged in any related party transactions that would affect its independence[160]. - The company has scheduled multiple shareholder meetings throughout 2024, with the first one on February 19, 2024[160]. - The company has not reported any requests for temporary shareholder meetings from preferred shareholders[162]. - The company is focused on improving its governance structure through amendments to its articles of association and meeting rules[169].